HK2 and ovarian cancer: In addition, SPARC shows dose-dependent inhibition of HK2 activity and decreased mitochondrial activity on human and mouse ovarian cancer cell lines, which is related to the energy metabolism of tumor metastasis (Naczki et al., 2018).